By using an assay system based on a human hepatoblastoma cell line (HB611) that continuously synthesizes hepatitis B virus (HBV) DNA, 56 acyclic nucleoside phosphonate analogues were examined for their inhibitory effects on HBV DNA synthesis. The following compounds were found to inhibit HBV DNA synthesis at concentrations that were significantly lower than their minimum cytotoxic concentrations; 9-(2-phosphonylmethoxyethyl)adenine (PMEA), 9-(2-phosphonylmethoxyethyl) guanine(PMEG), 9-(2-phosphonylmethoxyethyl) guanine ethyl ester (PMEGEE), 9 - (2 - phosphonylmethoxyethyl) - 1 - deazaadenine (PMEC1A), 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP), (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine (HPMPA), 9-(3-isopropoxy-2-phosphonylmethoxypropyl)adenine (IPPMPA), 9-(RS)-(2-phosphonylmethoxypropyl)adenine (PMPA) and 9-(3-hydroxy-2-phosphonylmethoxypropyl)-2, 6-diaminopurine (HPMPDAP). The most selective compounds (with indexes greater than 100) were PMEDAP, PMEA, IPPMPA, and PMPA. Acyclic pyrimidine nucleoside phosphonate analogues did not prove markedly selective as anti-HBV agents. Diphosphoryl derivatives of some acyclic purine nucleoside phos-phonates (i.e. PMEA, PMEDAP, HPMPA) were prepared. They proved inhibitory to HBV DNA polymerase but not cellular DNA polymerase α.
References
1.
ArzuzaO.Garcia-VillalonD.TabaresE.Gil-FernandezC., and De ClercqE. (1988) Inhibition of African swine fever virus DNA synthesis by (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine. Biochem Biophys Res Commun154: 27–32.
2.
BalzariniJ.NaesensL.HerdewijinP.RosenbergI.HoluA.PauwelsR.BabaM.JohnsD.G., and De ClercqE. (1989) Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine, a selective antihuman immunodeficiency virus agent. Proc Natl Acad Sci, USA86: 332–336.
3.
BalzariniJ.NaesensL., and De ClercqE. (1990) Anti-retrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) in vivo increases when it is less frequently administered. Int J Cancer46: 337–340.
4.
BalzariniJ.NaesensL.SlachmuyldersJ.NiphuisH.RosenbergI.HolyA.SchellekensH., and De ClercqE. (1991a) 9-(2-phosphonylmethoxyethyl)adenine (PMEA) effectively inhibits retrovirus replication in vitro and simian immunodeficiency virus (SIV) infection in rhesus monkeys. AIDS5: 21–28.
5.
BalzariniJ.HaoZ.HerdewijinP.JohnsD.G., and De ClercqE. (1991b) Intracellular metabolism and mechanism of antiretrovirus action of 9-(2-phosphonylmethoxyethyl)adenine (PMEA), a potent anti-HIV compound. Proc Nat Acad Sci, USA88: 1499–1503.
6.
De CastroL.M.KernE.R.De ClercqE.GhaffarA.MayerE.P.VogtP.E., and GangemiJ.D. (1991) Phosphonylmethoxyalkyl purine and pyrimidine derivatives for treatment of opportunistic cytomegalovirus and herpes simplex virus infections in murine AIDS. Antiviral Res16: 101–114.
7.
De ClercqE.HolyA.RosenbergI.SakumaT.BalzariniJ., and MagudgalP.C. (1986) A novel selective broad-spectrum anti-DNA virus agent. Nature323: 464–467.
8.
De ClercqE.SakumaT.BabaM.PauwelsR.BalzariniJ.RosenbergI., and HolyA. (1987) Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Res8: 261–272.
9.
Del GobboV.FoliA.BalzariniJ.De ClercqE.BalestraE.VillaniN.MariniS.FedericoC., and CalioS. (1991) Immunomodulatory activity of 9-(2-phosphonylmethoxyethyl)adenine (PMEA), a potent anti-HIV nucleotide analogue, on in vivo murine models. Antiviral Res16: 65–75.
10.
EgberinkH.BorstM.NiphuisH.BalzariniJ.NeuH.SchellekensH.De ClercqE.HorzinekM., and KoolenM. (1990) Suppression of feline immunodeficiency virus infection in vivo by 9-(2-phosphonylmethoxyethyl)adenine. Proc Natl Acad Sci, USA87: 3087–3091.
11.
GangemiJ.D.CozensR.M.De ClercqE.BalzariniJ., and HochkeppelH.-K. (1989) 9-(2-phosphonylmethoxyethyl) adenine in the treatment of murine acquired immuno-deficiency disease and opportunistic herpes simplex virus infections. Antimicrob Agents Chemother33: 1864–1868.
12.
HolyA., and RosenbergI. (1987) Synthesis of 9-(2-phosphonylmethoxyethyl)adenine and related compounds. CollectCzech Chem comm52: 2801–2809.
13.
HooverE.A.EbnerJ.P.ZeidnerN.S., and MullinsJ.I. (1991) Early therapy of feline leukemia virus infection (FeLV-FAIDS) with 9-(2-phosphonylmethoxyethyl) adenine (PMEA). Antiviral Res16: 77–92.
14.
MaudgalP.C., and De ClercqE. (1991) Effects of phosphonyl-methoxyalkylpurine and -pyrimidine derivatives on TK+ and TK-HSV-1 keratitis in rabbits. Antiviral Res16: 93–100.
15.
MeiselH.ReimerK.Von Janta-LipinskiM.BarwoelffD., and MathesE. (1990) Inhibition of hepatitis B virus DNA polymerase by 3′-fluorothymidine triphosphate and other modified nucleoside triphosphate analogs. J Med Virol30: 137–141.
16.
NaesensL.BalzariniJ.RosenbergI.HolyA., and De ClercqE. (1989) 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP); a novel agent with anti-human immunodeficiency virus activity in vitro and potent anti-Moloney murine sarcoma virus activity in vivo. Eur J Clin Microb Infect Dis8: 1043–1047.
17.
NaesensL.BalzariniJ., and De ClercqE. (1991) Single-dose administration of 9-(2-phosphonylmethoxyethyl) adenine (PMEA) and 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP) in the prophylaxis of retrovirus infection in vivo. Antiviral Res16: 53–64.
18.
PaluG.StefanelliS.RassuM.ParolinC.BalzariniJ., and De ClercqE. (1991) Cellular uptake of phosphonylmethoxyalkyl-purine derivatives. Antiviral Res16: 115–119.
19.
PauwelsR.BalzariniJ.ScholsD.BabaM.DesmyterJ.RosenbergI.HolyA., and De ClercqE. (1988) Phosphonyl-methoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents. Antimicrob Agents Chemother32: 1025–1030.
20.
UedaK.TsurimotoT.NagahataT.ChisakaO., and MatsubaraK. (1989) An in vitro system for screening anti-hepatitis B virus drugs. Virology169: 213–216.
21.
VotrubaI.BernaertsR.SakumaT.De ClercqE.MertaA.RosenbergI., and HolyA. (1987) Intracellular phosphorylation of broad-spectrum anti-DNA virus agent (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine and inhibition of viral DNA synthesis. Mol Pharmacol32: 524–529.
22.
YokotaT.KonnoK.ShigetaS., and De ClercqE. (1984) Comparative inhibition of DNA polymerase from varicella zoster virus (TK+ and TK−) strain by (E)-5-(2-bromovinyl)-2′-deoxyu-ridine 5′-triphosphoate. Mol Pharmacol26: 376–380.
23.
YokotaT.KonnoK.ChonanE.MochizukiS.KojimaK.ShigetaS., and De ClercqE. (1990) Comparative activities of several nucleoside analogs against duck hepatitis B virus in vitro. Antimicrob Agent Chemother34: 1326–1330.
24.
YokotaT.MochizikiS.KonnoK.MoriS.ShigetaS., and De ClercqE. (1991) Inhibitory effects of selected compounds on human hepatitis B virus DNA synthesis. Antimicrob Agent Chemother35: 394–397.
